Congenital Heart Disease

  1. Overview and Epidemiology
  2. Classification: Acyanotic vs. Cyanotic
  3. Acyanotic Defects — Left-to-Right Shunts
  4. Cyanotic Defects — Right-to-Left Shunts
  5. Etiology and Risk Factors
  6. Diagnosis and Newborn Screening
  7. Treatment and Interventions
  8. Eisenmenger Syndrome
  9. Outcomes and Long-Term Care
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview and Epidemiology

Congenital heart disease (CHD) refers to structural abnormalities of the heart or great vessels present from birth, resulting from abnormal cardiac development during the first 8 weeks of embryogenesis. It is the most common congenital abnormality in humans, affecting approximately 0.8–1% of all live births — roughly 40,000 newborns per year in the United States and 1.35 million worldwide annually.

The spectrum of CHD ranges from simple, hemodynamically trivial defects that close spontaneously (such as small muscular ventricular septal defects) to complex single-ventricle anomalies that require multiple staged surgical palliations over the first years of life. Approximately 25% of children with CHD have a critical lesion requiring intervention within the first year of life; without timely diagnosis and treatment, many of these lesions are fatal in the neonatal or early infant period.

Advances in pediatric cardiac surgery and catheter-based interventions have transformed outcomes dramatically. Where once many children with complex CHD did not survive to adulthood, today more than 90% of CHD patients survive to adulthood, creating a large and growing population of adults with congenital heart disease (ACHD) who require lifelong specialized cardiology follow-up. There are now more adults living with CHD in the US than children — approximately 1.4 million adults versus 1 million children (Marelli et al., 2007).

CHD carries a significant burden even in high-income countries: it accounts for approximately $6 billion in annual hospital charges in the US, and children with complex CHD have disproportionately high rates of neurodevelopmental delay, growth restriction, and recurrent hospitalizations. In low- and middle-income countries, where surgical capacity is limited, CHD remains a leading cause of preventable childhood mortality.

Back to Table of Contents

Classification: Acyanotic vs. Cyanotic

The traditional classification of CHD into acyanotic and cyanotic lesions is based on the direction of intracardiac shunting and its effect on systemic oxygen saturation. While modern classification systems also incorporate anatomical and hemodynamic complexity (single-ventricle vs. biventricular circulation; duct-dependent vs. non-duct-dependent), the acyanotic/cyanotic framework remains foundational for clinical reasoning at presentation.

Acyanotic CHD (left-to-right shunts): In these defects, a structural communication between the left and right sides of the heart — or between the aorta and pulmonary artery — allows oxygenated blood (higher pressure, left side) to recirculate through the pulmonary circulation. Because blood shunted right still passes through the lungs before returning to the systemic circulation, systemic oxygen saturation is initially normal. The clinical consequence is pulmonary overcirculation and volume overload of the right heart and pulmonary vasculature rather than cyanosis. Over time, sustained high pulmonary blood flow can cause pulmonary hypertension, which if uncorrected may reverse the shunt (Eisenmenger syndrome).

Cyanotic CHD (right-to-left shunts): In these defects, deoxygenated venous blood bypasses the pulmonary circulation entirely or partially and enters the systemic arterial system. The result is central cyanosis — a blue-purple discoloration of the lips, tongue, and mucous membranes that reflects reduced oxyhemoglobin saturation. Peripheral cyanosis (acrocyanosis of hands and feet) is a normal finding in newborns due to vasomotor instability and does not indicate CHD; central cyanosis on pulse oximetry or arterial blood gas is the diagnostic trigger.

A useful clinical test is the hyperoxia test (nitrogen washout test): the infant breathes 100% oxygen for 10 minutes. In cyanosis from respiratory disease, PaO2 typically rises above 150–200 mmHg; in cyanotic CHD with fixed right-to-left shunting, PaO2 typically remains below 150 mmHg because oxygenated blood from the lungs mixes with fixed amounts of deoxygenated shunted blood. This test guides urgent echocardiography.

Back to Table of Contents

Acyanotic Defects — Left-to-Right Shunts

Ventricular Septal Defect (VSD) is the most common congenital heart defect, accounting for approximately 30% of all CHD. A VSD is an opening in the interventricular septum. The four anatomical types — perimembranous (most common, 70%), muscular, outlet (supracristal), and inlet (atrioventricular canal-type) — differ in their location, tendency to close spontaneously, and associated anomalies. Small muscular VSDs close spontaneously in up to 80% of cases within the first 2 years of life. Large VSDs cause excessive pulmonary blood flow, congestive heart failure (poor feeding, diaphoresis with feeds, failure to thrive, tachypnea), and require surgical or catheter-based closure before 6 months to prevent pulmonary vascular disease.

Atrial Septal Defect (ASD) accounts for approximately 10% of CHD. The most common type is the secundum ASD (central fossa ovalis region, 70% of ASDs), followed by primum (lower septum, associated with AVSD and mitral cleft), sinus venosus (upper septum, associated with anomalous pulmonary venous drainage), and coronary sinus type. ASDs are often asymptomatic in childhood (the right ventricular compliance buffers the shunt); presentations include a fixed widely split S2, a pulmonary flow murmur, and — in adulthood — atrial arrhythmias and paradoxical embolism. Most secundum ASDs are now closed via catheter-delivered occluder devices (Amplatzer, Gore Cardioform) rather than open surgery.

Patent Ductus Arteriosus (PDA) is persistence of the fetal ductus arteriosus (a normal channel connecting the main pulmonary artery to the descending aorta that diverts blood away from the unexpanded fetal lungs) after birth. In term neonates the ductus normally closes within 24–72 hours in response to rising postnatal oxygen tension and falling prostaglandin levels. Persistent PDA creates a left-to-right shunt from aorta to pulmonary artery. PDA is extremely common in premature infants (up to 80% of infants <28 weeks gestation) due to immature oxygen sensitivity of ductal smooth muscle. Classic findings: continuous "machinery" murmur at the left upper sternal border, wide pulse pressure, bounding peripheral pulses. Treatment: indomethacin or ibuprofen (COX inhibitors reduce prostaglandin synthesis to promote ductal closure); surgical ligation or catheter-based occlusion for persistent cases.

Atrioventricular Septal Defect (AVSD) — also called endocardial cushion defect — involves a deficiency of the crux of the heart: a combination of an ostium primum ASD, an inlet VSD, and a common AV valve replacing separate mitral and tricuspid valves. AVSD is strongly associated with trisomy 21 (Down syndrome), occurring in 40–45% of children with Down syndrome who have CHD. Complete AVSD causes severe pulmonary overcirculation requiring surgical repair at 3–6 months of age.

Coarctation of the Aorta (CoA) is a discrete narrowing of the aorta, almost always at the junction of the aortic arch and descending aorta near the ductus arteriosus insertion (juxtaductal). The narrowing creates a pressure gradient between the upper and lower body: hypertension in the upper extremities, diminished or delayed femoral pulses, lower blood pressure in the legs. In severe neonatal CoA, when the ductus closes, lower-body perfusion depends entirely on the narrowed segment — producing shock, acidosis, and acute left ventricular failure. Prostaglandin E1 is life-saving by reopening the ductus. Late diagnosis in older children presents as upper extremity hypertension, headaches, and rib notching from collateral intercostal artery formation visible on chest X-ray. Associated with Turner syndrome (bicuspid aortic valve in 50–85%).

Back to Table of Contents

Cyanotic Defects — Right-to-Left Shunts

Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect, accounting for approximately 7–10% of all CHD. The anatomical tetrad consists of: (1) VSD (large, perimembranous, subarterial); (2) pulmonic stenosis (subpulmonary infundibular obstruction primarily, with or without valvular component); (3) overriding aorta (aorta straddles the VSD, receiving blood from both ventricles); (4) right ventricular hypertrophy (secondary to outflow obstruction). The unifying embryological defect is anterior deviation of the outlet septum, which simultaneously creates the infundibular obstruction and the malaligned VSD.

Hemodynamically, the key variable is the degree of right ventricular outflow tract (RVOT) obstruction. Mild obstruction → balanced or net left-to-right shunt → "pink tet" (acyanotic at rest). Severe obstruction → right-to-left shunting through the VSD → central cyanosis. The classic "tet spells" (hypercyanotic episodes) are acute increases in right-to-left shunting triggered by crying, feeding, or defecation (increased oxygen demand + dynamic RVOT spasm + decreased systemic vascular resistance). Infants draw up their knees to their chest or squat when older — this maneuver increases systemic vascular resistance (kinking femoral arteries), reduces right-to-left shunting, and relieves the spell. Medical management of tet spells: knee-chest position, supplemental oxygen, morphine (reduces hyperpnea, sedates), phenylephrine (raises SVR), IV propranolol (reduces RVOT spasm). Surgical correction (VSD closure + RVOT relief) is planned electively at 3–6 months.

Transposition of the Great Arteries (TGA) — the aorta arises from the morphological right ventricle and the pulmonary artery from the left ventricle, creating parallel rather than series circulations: systemic venous blood recirculates to the body without passing through the lungs, and pulmonary venous blood recirculates through the lungs. This is hemodynamically incompatible with sustained life unless mixing exists between the two circuits (via ASD, VSD, or PDA). TGA presents as severe cyanosis in the first hours of life in an otherwise vigorous-appearing newborn (lungs are normal, cardiac output initially adequate). Emergency management: prostaglandin E1 to maintain PDA + emergent balloon atrial septostomy (Rashkind procedure) to create an ASD for mixing. Definitive treatment: arterial switch operation (Jatene procedure) within the first 2 weeks of life — the great arteries are transposed back to their correct ventricles and the coronary arteries are reimplanted into the neoaorta.

Truncus Arteriosus: A single great artery (truncus) arises from the heart and gives rise to the aorta, pulmonary arteries, and coronary arteries. There is always an associated VSD beneath the truncal valve. Presents with cyanosis plus pulmonary overcirculation (both systemic and pulmonary circuits arise from the single vessel). Associated with 22q11.2 deletion (DiGeorge syndrome) in 35–40% of cases. Surgical repair with VSD closure and placement of a right ventricle-to-pulmonary artery conduit is performed in the neonatal period.

Hypoplastic Left Heart Syndrome (HLHS): Severe underdevelopment of left-sided structures — hypoplastic left ventricle, mitral atresia or severe stenosis, aortic atresia, and hypoplastic ascending aorta. The entire systemic circulation depends on the right ventricle via a PDA; systemic perfusion collapses when the ductus closes. Prostaglandin E1 is immediately life-sustaining. Surgical treatment follows the Norwood staged palliation (Stage I Norwood operation in the newborn period; Stage II bidirectional Glenn at 4–6 months; Stage III Fontan completion at 2–4 years) — converting the single right ventricle to power the systemic circulation while passive venous pressure drives pulmonary blood flow. Cardiac transplantation is an alternative. HLHS accounts for 23–25% of cardiac deaths in the first week of life.

Total Anomalous Pulmonary Venous Return (TAPVR): All four pulmonary veins drain to the systemic venous circulation (right atrium, superior vena cava, coronary sinus, or infradiaphragmatic via portal system) rather than the left atrium. Mixing occurs at the ASD (obligatory for survival). Obstructed TAPVR (particularly infradiaphragmatic) presents as a cardiac emergency at birth with profound cyanosis, pulmonary edema, and respiratory failure — requires emergency surgery within hours.

Back to Table of Contents

Etiology and Risk Factors

CHD results from the interaction of genetic predisposition and environmental exposures during the critical period of cardiac morphogenesis (weeks 3–8 of gestation). Most CHD is multifactorial: isolated CHD without chromosomal anomaly has a recurrence risk of approximately 3–5% in siblings — substantially above the population rate but well below classic single-gene Mendelian inheritance.

Chromosomal anomalies associated with CHD:

Teratogenic and maternal environmental exposures:

Back to Table of Contents

Diagnosis and Newborn Screening

Prenatal echocardiography is now the primary tool for antenatal CHD detection. Detailed fetal echo by a pediatric cardiologist is recommended for pregnancies with increased CHD risk (family history of CHD, maternal diabetes, suspected fetal anomaly on anatomic ultrasound, known teratogen exposure, chromosomal anomaly). The standard obstetric four-chamber view at the 18–20 week anatomy scan detects approximately 40–60% of significant CHD; adding outflow tract views increases sensitivity to 70–80%. Dedicated fetal echocardiography detects over 90% of major lesions.

Pulse oximetry newborn screening (CCHD screening) became standard in US hospitals following the 2011 recommendation by the Department of Health and Human Services and is now required by law in all 50 states. The protocol screens for critical congenital heart disease (CCHD) — the seven "target conditions" (HLHS, pulmonary atresia, TOF, TAPVR, TGA, tricuspid atresia, truncus arteriosus) plus severe CoA — which account for most cardiac deaths in the first week of life.

Screening is performed at 24–48 hours of age (or as late as possible before discharge for early discharges). Oxygen saturation is measured on the right hand (preductal) and either foot (postductal). A positive screen requires echocardiography. Studies show newborn pulse oximetry screening has a sensitivity of 76–78% for CCHD with a false-positive rate of only 0.035% — preventing an estimated 160–400 infant deaths annually in the US (Peterson et al., 2014).

Postnatal echocardiography is the gold standard for postnatal CHD diagnosis, providing detailed anatomical and hemodynamic information without radiation. Doppler evaluation quantifies pressure gradients and shunt magnitude. Color-flow mapping visualizes intracardiac flow direction.

Cardiac catheterization is now primarily reserved for interventional procedures (balloon valvuloplasty, device closure, stent placement) and hemodynamic assessment when non-invasive data are insufficient — particularly pulmonary vascular resistance measurement before Fontan completion or surgical repair in patients with suspected pulmonary hypertension.

Chest X-ray: Nonspecific but provides rapid data on cardiomegaly (cardiothoracic ratio >0.55 in infants), pulmonary vascular markings (increased in left-to-right shunts, decreased in pulmonic stenosis or TOF), and aortic arch sidedness. Classic XR patterns: "boot-shaped heart" in TOF (upturned cardiac apex from RVH), "egg on a string" in TGA (narrow mediastinum from parallel great vessels), "snowman" sign in supracardiac TAPVR (mediastinal widening from dilated venous confluence).

Back to Table of Contents

Treatment and Interventions

Prostaglandin E1 (alprostadil) is the cornerstone of initial management for any duct-dependent CHD — lesions in which either pulmonary or systemic perfusion depends on a patent ductus arteriosus. This includes: HLHS, critical aortic stenosis, interrupted aortic arch, critical CoA (systemic duct-dependent); pulmonary atresia, critical pulmonic stenosis, tricuspid atresia, TGA without adequate mixing (pulmonary duct-dependent). Prostaglandin E1 relaxes ductal smooth muscle and maintains or reopens the ductus. Continuous IV infusion at 0.01–0.1 mcg/kg/min. Key side effects: apnea (may require intubation), fever, hypotension. Critically important: any newborn with unexplained cyanosis, shock, or ductal-dependent physiology should receive prostaglandin E1 empirically while awaiting echocardiography — the benefit far outweighs the risk of treating unnecessarily.

Balloon atrial septostomy (Rashkind procedure): Performed emergently in TGA when an ASD is inadequate for mixing. A balloon catheter is advanced through the foramen ovale into the left atrium, inflated, then pulled back forcefully to tear the atrial septum, creating a large ASD. Can be performed at the bedside in the NICU under echocardiographic guidance. Palliates TGA until arterial switch surgery.

Catheter-based interventions have replaced open surgery for many lesions:

Surgical repair remains necessary for complex lesions. Major advances include: neonatal arterial switch for TGA (Jatene, 1984); complete intracardiac repair of TOF in infancy; staged Norwood palliation for HLHS; repair of complete AVSD; neonatal repair of TAPVR. The development of cardiopulmonary bypass in the 1950s (Gibbon, 1953) and progressive refinements in neonatal cardiac anesthesia, myocardial protection, and postoperative critical care have transformed survival for lesions once universally fatal.

Antibiotic prophylaxis for endocarditis: Per 2007 AHA guidelines, IE prophylaxis is no longer recommended for most CHD patients before dental procedures. It is still recommended for: unrepaired cyanotic CHD; repaired CHD with residual defects at or adjacent to prosthetic material; within 6 months of surgical or device repair (until re-endothelialization); and cardiac transplantation with valvulopathy. This represents a significant departure from prior universal prophylaxis that was based on limited evidence.

Back to Table of Contents

Eisenmenger Syndrome

Eisenmenger syndrome represents the most severe consequence of untreated large left-to-right shunts. Sustained high pulmonary blood flow from a large VSD, ASD, PDA, or AVSD subjects the pulmonary vasculature to chronic volume and pressure overload, triggering irreversible structural changes in the pulmonary arterioles: medial hypertrophy, intimal proliferation, plexiform lesion formation, and eventual fibrosis. These changes progressively raise pulmonary vascular resistance (PVR).

When PVR approaches or exceeds systemic vascular resistance, the net direction of shunting reverses — from the original left-to-right to a now right-to-left shunt. This reversal is accompanied by central cyanosis (late-onset, appearing in adolescence or early adulthood after years of asymptomatic left-to-right shunting), dyspnea on exertion, polycythemia (secondary erythrocytosis from chronic hypoxia), hyperviscosity, thromboembolism, and hemoptysis.

The tragedy of Eisenmenger syndrome is that once it develops, the intracardiac defect can no longer be surgically closed — the shunt is now functioning as a pressure-relief valve for the high-pressure right heart; closing it would precipitate acute right heart failure and death. Management is palliative with pulmonary vasodilator therapies (bosentan, sildenafil, prostacyclin analogs — the same agents used for idiopathic pulmonary arterial hypertension) to reduce PVR, improve symptoms, and slow progression. Heart-lung transplantation or combined cardiac-lung transplantation is the only definitive treatment option. Eisenmenger syndrome historically carried a median survival of 20–30 years from the time of diagnosis, though modern vasodilator therapy is improving this trajectory.

Eisenmenger syndrome underscores the importance of timely repair of significant shunts in infancy and early childhood — before irreversible pulmonary vascular disease develops. With modern newborn screening and early surgical access, Eisenmenger syndrome is becoming increasingly rare in high-income countries, though it remains a major problem in regions with limited surgical capacity.

Back to Table of Contents

Outcomes and Long-Term Care

Survival after CHD repair has improved dramatically. Overall 1-year survival for all CHD is now above 97% in experienced centers; for complex lesions such as TOF, operative mortality is below 2% at specialized centers. However, CHD is rarely "cured" — most patients require lifelong cardiology follow-up, and many face late complications including arrhythmias, residual hemodynamic lesions, ventricular dysfunction, and the need for reintervention.

Neurodevelopmental outcomes are a major concern. Children with complex CHD — particularly those requiring neonatal cardiac surgery with cardiopulmonary bypass and deep hypothermic circulatory arrest — have elevated rates of developmental delay, learning disabilities, attention deficit disorder, and executive function deficits. The causes are multifactorial: perioperative brain injury, chronic cerebral hypoperfusion during gestation, genetic syndromes (22q11.2, trisomy 21) with independent neurodevelopmental effects, and prolonged hospitalizations disrupting developmental opportunities. The American Heart Association recommends routine neurodevelopmental evaluation for complex CHD survivors at school age.

Adults with congenital heart disease (ACHD) now outnumber children with CHD in absolute numbers. This population requires specialized care from cardiologists trained in adult CHD (ACHD) — a distinct subspecialty addressing late complications such as: atrial arrhythmias (particularly after Fontan completion or atrial baffling procedures), ventricular dysfunction (RV in systemic position after atrial switch, single-ventricle Fontan physiology), neoaortic dilation in TOF or after arterial switch, conduit failure requiring repeat surgery or transcatheter valve replacement, and obstetric management during pregnancy (CHD is the leading cause of non-obstetric maternal mortality in pregnancy in high-income countries).

Physical activity guidance is individualized. Most patients with repaired simple CHD (small VSD, secundum ASD, mild PS) can participate in full competitive sports. Patients with residual hemodynamic lesions, significant ventricular dysfunction, or aortic dilation require modified activity recommendations based on current ACC/AHA guidelines for competitive athletes with CHD.

Back to Table of Contents

Key Research Papers

  1. van der Linde D, et al. (2011). Global birth prevalence of congenital heart defects 1970–2010. Journal of the American College of Cardiology, 58(21), 2241–2247. PMID: 22078432 — Systematic review establishing global CHD birth prevalence of 9 per 1,000 live births (range 6–13).
  2. Marelli AJ, et al. (2007). Congenital heart disease in the general population. Circulation, 115(2), 163–172. PMID: 17210844 — Population-based study showing adults with CHD now outnumber children with CHD in developed nations.
  3. Jatene AD, et al. (1976). Anatomic correction of transposition of the great vessels. Journal of Thoracic and Cardiovascular Surgery, 72(3), 364–370. PMID: 61409 — Landmark description of the arterial switch operation that transformed TGA from a near-universally fatal diagnosis to one with excellent long-term survival.
  4. Norwood WI Jr, et al. (1983). Physiologic repair of aortic atresia-hypoplastic left heart syndrome. New England Journal of Medicine, 308(1), 23–26. PMID: 6336883 — Original description of the staged Norwood palliation for HLHS, converting a universally fatal diagnosis to one with long-term survivors.
  5. Peterson C, et al. (2014). Improving newborn screening for critical congenital heart disease. Pediatrics, 134(6), e1455–e1464. PMID: 25332497 — US population-based evaluation of pulse oximetry CCHD screening demonstrating 76% sensitivity and prevention of CCHD deaths.
  6. Marino BS, et al. (2012). Neurodevelopmental outcomes in children with congenital heart disease. Circulation, 126(9), 1143–1172. PMID: 22851541 — AHA scientific statement on elevated rates of neurodevelopmental morbidity in complex CHD survivors and recommendations for routine evaluation.
  7. Rastelli GC, et al. (1969). Anatomic correction of transposition with ventricular septal defect and subpulmonary stenosis. Journal of Thoracic and Cardiovascular Surgery, 58(4), 545–552. PMID: 5344694 — Classic description of the Rastelli procedure for TGA/VSD/LVOTO, an important alternative to arterial switch in specific anatomical variants.
  8. Humpl T, et al. (2003). Balloon atrial septostomy in neonates. Circulation, 107(8), 1132–1135. PMID: 12615790 — Contemporary series confirming safety and efficacy of Rashkind balloon atrial septostomy under echocardiographic guidance in the ICU setting.
  9. Hoffman JI, Kaplan S. (2002). The incidence of congenital heart disease. Journal of the American College of Cardiology, 39(12), 1890–1900. PMID: 12084585 — Comprehensive review of CHD epidemiology by lesion subtype providing the foundational frequency data used in clinical teaching.
  10. Wilson W, et al. (2007). Prevention of infective endocarditis. Circulation, 116(15), 1736–1754. PMID: 17446442 — 2007 AHA guidelines significantly restricting IE antibiotic prophylaxis to specific high-risk cardiac conditions.
  11. Gilboa SM, et al. (2016). Congenital heart defects in the United States. Circulation, 134(2), 101–109. PMID: 27353444 — National population-based estimates of CHD burden using linked vital statistics and hospital discharge data.
  12. Moons P, et al. (2010). Outcome measures in adult congenital heart disease. European Heart Journal, 31(23), 2883–2889. PMID: 20709720 — Framework for measuring outcomes in the growing ACHD population, covering functional status, quality of life, and late complications.

Additional PubMed searches:
Congenital heart disease newborn screening | Tetralogy of Fallot surgical outcomes | HLHS Norwood palliation

Back to Table of Contents

Connections

Back to Table of Contents